PVLA Pieris Pharma: Price-to-Projected Revenue Ratio
Pieris Pharmaceuticals (PVLA) is mitigating operational risks by diversifying its partnerships for the development of cancer therapy proteins. The forward P/S ratio on the GURU.Markets chart shows that the current metric is 821.20. The molecule pipeline is currently undergoing a restructuring phase with R&D constraints. Business success depends on the clinical test results of anti-kallikreins and the ability to attract new capital.
Comprehensive metric breakdowns and analytics for Pieris Corp (PVLA)
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- debt burden and liquidity indicators:
Debt to Equity Pieris Pharmaceuticals|PVLA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Pieris Pharmaceuticals|PVLA - Company Total Debt Obligations|Debt to Book Capitalization Ratio Pieris Corp|PVLA - Long-Term Debt Volume|Company Current Liabilities Pieris Pharmaceuticals|Quick Liquidity pieris.com
- financial results and valuation multiples details:
PVLA - Profit After Tax|Projected Future Earnings Pieris Pharmaceuticals|PVLA - Company Value to Net Income|Forward P/E Multiple Pieris Pharmaceuticals Inc|PVLA - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Corp|PVLA - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Pieris Pharmaceuticals|PVLA - Net earnings per share for the last 12 months|Quarterly EPS earnings growth pieris.com|PVLA - Earnings growth in current year|Earnings growth forecast for next year Pieris Pharmaceuticals
- sales volume and revenue indicators:
Comprehensive company analysis:PVLA (Pieris Pharmaceuticals, Inc.)
Pieris Pharmaceuticals (PVLA) is optimizing its innovative protein supply chains to ensure the continuity of clinical trials. The forward P/S is calculated as the ratio of current market capitalization to expected annual revenue, measuring the cost of every dollar of future sales. Investors utilize this multiple to assess whether the premium for potential business growth is justified. By analyzing forward P/S dynamics, one can determine the actual speed of asset revaluation by the market.
Analysis of competing companies
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|ABVX - Price-to-Projected Revenue Ratio|Future Price to Revenue ADMA|PTGX: Forward P/S Multiple|IMVT - Market Cap to Expected Sales Ratio|KNSA (Kiniksa) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Grifols SA GRFS|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|CLDX (Celldex Corp) - Forward Price to Sales|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|Market Cap to Expected Sales Ratio biocryst.com (BCRX)|VERA - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Dianthus Therapeutics Inc DNTH|PHVS (Pharvaris Corp) - Forward Price-to-Revenue Multiple|AbCellera Corp - Forward Price to Sales|Price-to-Projected Revenue Ratio Tourmaline Bio, Inc.|precigen.com - Future Price to Revenue|Forward P/S Multiple PHAR|NKTR (Nektar Therapeutics Inc) - Forward Price to Sales|Forward P/S Multiple UPB (Upstream Bio Corp)|Forward P/S Multiple Zenas Corp ZBIO|IMNM - Price-to-Projected Revenue Ratio|Forward Price to Sales GOSS (gossamerbio.com)|KalVista Pharmaceuticals, Inc. (KALV) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Septerna, Inc.|SVRA (Savara Corp) - Forward P/S Multiple|Forward P/S Multiple Rigel Corp|Forward P/S Multiple ANAB|Forward Price-to-Revenue Multiple astriatx.com ATXS|Forward P/S Multiple ENGN (enGene)|RAPT Therapeutics Inc. (RAPT) - Market Cap to Future Revenue Ratio|JBIO: Forward Price-to-Revenue Multiple|ACRS - Forward P/S Multiple|KYTX (Kyverna Therapeutics) - Forward Price-to-Revenue Multiple|TLSA: Price to Expected Revenue Ratio|CABA (Cabaletta Bio) - Forward P/S Multiple|Ventyx Biosciences Inc. (VTYX) - Market Cap to Expected Sales Ratio|Forward P/S Multiple THTX|Forward Price-to-Revenue Multiple Avalo Therapeutics Inc AVTX|Forward P/S Multiple ELDN (Eledon Pharmaceuticals)|Forward P/S Multiple agenusbio.com AGEN|CLYM - Price-to-Projected Revenue Ratio|ZURA: Price-to-Projected Revenue Ratio|aTyr (ATYR) - Price-to-Projected Revenue Ratio|ADAG - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio ImageneBio|Shattuck Therapeutics - Future Price to Revenue|Forward Price-to-Revenue Multiple EQ (Equillium, Inc.)|Price-to-Projected Revenue Ratio CNTB (connectbiopharm.com)|Price-to-Projected Revenue Ratio Immunic IMUX|Atara Biotherapeutics, Inc. - Price-to-Projected Revenue Ratio|InflaRx GmbH - Forward P/S Multiple|XFOR - Forward P/S Multiple|adicetbio.com (ACET) - Price-to-Projected Revenue Ratio|Future Price to Revenue CELU (Celularity)|INMB (INmune Bio Corp) - Forward P/S Multiple|BRNS: Forward Price to Sales|Forward P/S Multiple KZR|Forward P/S Multiple sabbiotherapeutics.com (SABS)|Price-to-Projected Revenue Ratio Akari Therapeutics Plc AKTX|Forward Price to Sales ENLV|QTTB - Price-to-Projected Revenue Ratio|GeoVax Corp (GOVX) - Forward Price-to-Revenue Multiple|EDSA: Forward P/S Multiple|ibioinc.com (IBIO) - Forward P/S Multiple|Forward Price-to-Revenue Multiple CARM|XTLB: Forward Price to Sales|Forward P/S Multiple BOLT|Market Cap to Expected Sales Ratio hcwbiologics.com|Price-to-Projected Revenue Ratio Aptevo Therapeutics Inc. APVO|AIM - Forward Price-to-Revenue Multiple|ADTX - Price-to-Projected Revenue Ratio|GRI Bio Inc (GRI) - Forward Price-to-Revenue Multiple|XRTX (XORTX) - Forward Price-to-Revenue Multiple|Vyome Therapeutics (HIND) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Revelation Biosciences|Market Cap to Projected Revenue INDP (indaptusrx.com)|Forward P/S Multiple SCNI|CALI - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Affimed N.V. AFMD|ALLK (Allakos Inc) - Future Price to Revenue|HOOKIPA - Forward P/S Multiple|Market Cap to Expected Sales Ratio IGM Biosciences, Inc. IGMS|ITOS: Forward P/S Multiple|Market Cap to Future Revenue Ratio Ocean Biomedical Inc (OCEA)|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|THRD: Forward Price to Sales
